In the current pharmaceutical field, the market share for cell and antibody therapies is steadily increasing. These therapies hold great promise for patient benefit and medical progress, and are rapidly emerging as effective solutions to complex diseases. As the demand for these cutting-edge drugs grows, it has become a critical challenge to achieve efficient and stable large-scale production. In this process, bioreactors are able to play a crucial role.
Both traditional stainless steel bioreactors and newer single-use bioreactors come equipped with online monitoring and control features. This allows for real-time adjustments to key parameters such as temperature, pH, and dissolved oxygen (DO), helping to optimize the physiological conditions for cell processes and identify the best feeding strategies.
When evaluating bioreactor options, pharmaceutical companies primarily face challenges related to cost (stainless steel/disposable models) and scalability (flow field uniformity and shear force).
❖ Stainless steel bioreactors can be difficult to clean, requiring substantial cleaning data during production line changes to comply with GMP standards. This often results in significant time and validation costs for companies.
❖ Traditional stirred tank bioreactors can impose high shear stress, making it challenging to culture shear-sensitive cells such as iPSCs, NK cells, and MSCs on a large scale.
Morimatsu 2D Single-Use Bioreactor
Morimatsu 2D WAVE Single-Use Bioreactor is designed to better meet the experimental needs of customers by incorporating advanced foreign technology and cutting-edge design concepts. This bioreactor features a single-use reaction bag, which allows for lower initial investments and eliminates the cleaning time associated with batch changes, significantly reducing contamination risks.
Its unique two-dimensional rocking mode offers gas mass transfer capabilities comparable to traditional stirred tank bioreactors. At the same rotational speed, it generates lower fluid shear stress, creating a gentler growth environment ideal for stem cells and immune cells.
Application Examples
The 2D WAVE Single-Use Bioreactor has successfully facilitated the large-scale culture of HEK293, CHO, and MSC cells. It is capable of maintaining the same or higher cell viability than the stirred tank bioreactor at maximum cell growth density in the same volume.
HEK293 Cell Growth Data
CHO Cell Growth Data
MSC Cell Growth Data
MSC Cell Fluorescence Images
Experimental results demonstrate that the 2D WAVE Single-Use Bioreactor can support high-density growth of mainstream industrial cell lines. Under appropriate feeding conditions, it features a significantly higher cell proliferation capacity compared to stirred tank bioreactors. For mesenchymal stem cells that require microcarriers for growth, the 2D WAVE Single-Use Bioreactor effectively suspends these microcarriers, providing a uniform physiological environment for MSCs.
Morimatsu is committed to exploring cutting-edge technologies within the industry, using innovation as a driving force to deliver flexible and efficient solutions for biopharmaceutical research, development, and commercial production. This ongoing commitment will empower the high-quality development of the biopharmaceutical sector.
About Morimatsu LifeSciences
Morimatsu LifeSciences, one of the key business segments of Morimatsu International Holding Co., Ltd. (Morimatsu International, stock code: 2155.HK), mainly consists of Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd., Morimatsu (Suzhou) Life Technology Co., Ltd., Shanghai Morimatsu Biotechnology Co., Ltd., Pharmadule Morimatsu AB (Sweden) and its subsidiaries, which serves the pharmaceuticals, bio-pharmaceutical, cosmetic medicine, FMCG (cosmetics, baby, women & home Care, health care, fabric & home care, food, beverage, nutraceuticals) and other industries, providing customers with "core equipment+value-added services+digital intelligent overall factory solutions and services" ("MVP Solutions&Services"), focusing on core equipment, stainless steel process systems, disposable process systems, consumables, laboratory solutions, digital and modular factory solutions and services.
As a diversified multinational company, Morimatsu has opened subsidiaries or advanced manufacture plants in China, Japan, Sweden, United States, India, Italy, Singapore, and has delivered different forms of products and services to more than 40 countries and regions so far, by its global footprint of an efficient and professional team.
Forward-Looking Statements
The information in this press release may include some forward-looking statements. Such statements are essentially susceptible to considerable risks and uncertainties. The use of "predicted", "believed", "forecast", "planned" and/or other similar words/phrases in all statements related to our company is to indicate that the statements are forward-looking ones. Our Company undertakes no obligation to constantly revise such predicted statements.
Forward-looking statements are based on our Company management's current perspectives, assumptions, expectations, estimations, predictions and understanding of future affairs at the time of the making of such statements. Such statements are not guarantees of future development and are susceptible to the impact of risks, uncertainties and other factors; some are beyond the control of our Company and unpredictable. Subject to the influence of future changes and development in our business, competition environment, political, economic, legal and social conditions, the actual outcomes may differ significantly from the information contained in the forward-looking statements.